CTLA4 and melanoma: Similarly, Beck et al. [31] reported a 14% rate of response but a 21% rate of enterocolitis in patients with renal cell carcinoma or melanoma who received a human anti-CTLA-4 monoclonal antibody over a 3-year period with or without a peptide vaccine.